155 related articles for article (PubMed ID: 3700615)
1. Response of dairy calves to vaccinia viruses that express foreign genes.
Gillespie JH; Geissinger C; Scott FW; Higgins WP; Holmes DF; Perkus M; Mercer S; Paoletti E
J Clin Microbiol; 1986 Feb; 23(2):283-8. PubMed ID: 3700615
[TBL] [Abstract][Full Text] [Related]
2. Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.
Paoletti E; Lipinskas BR; Samsonoff C; Mercer S; Panicali D
Proc Natl Acad Sci U S A; 1984 Jan; 81(1):193-7. PubMed ID: 6320164
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity, pathogenicity, and transmissibility of a recombinant vaccinia virus in calves.
Wedman EE; Smith AW; Oliver RE
Am J Vet Res; 1988 Dec; 49(12):2018-21. PubMed ID: 3239835
[TBL] [Abstract][Full Text] [Related]
4. Immune response to vaccinia virus and recombinant virus products in dogs.
Appel MJ; Paoletti E
Am J Vet Res; 1988 Nov; 49(11):1932-4. PubMed ID: 2977718
[TBL] [Abstract][Full Text] [Related]
5. Recombinant vaccinia virus: immunization against multiple pathogens.
Perkus ME; Piccini A; Lipinskas BR; Paoletti E
Science; 1985 Sep; 229(4717):981-4. PubMed ID: 2992092
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus large surface protein is not secreted but is immunogenic when selectively expressed by recombinant vaccinia virus.
Cheng KC; Smith GL; Moss B
J Virol; 1986 Nov; 60(2):337-44. PubMed ID: 2430108
[TBL] [Abstract][Full Text] [Related]
7. Immunization with Varicella-zoster virus glycoprotein E expressing vectors: Comparison of antibody response to DNA vaccine and recombinant vaccinia virus.
Stasíková J; Kutinová L; Smahel M; Nĕmecková S
Acta Virol; 2003; 47(1):1-10. PubMed ID: 12828337
[TBL] [Abstract][Full Text] [Related]
8. Priming effect of recombinant vaccinia virus coding for the middle hepatitis B surface antigen.
Hamsíková E; Závadová H; Kutinová L; Ludvíková V; Krchnák V; Némecková S; Vonka V
Arch Virol; 1990; 113(3-4):283-9. PubMed ID: 2222186
[TBL] [Abstract][Full Text] [Related]
9. Live recombinant vaccines using genetically engineered vaccinia virus.
Paoletti E; Perkus ME; Piccini A
Antiviral Res; 1985; Suppl 1():301-7. PubMed ID: 3866514
[No Abstract] [Full Text] [Related]
10. Secondary vaccination with vaccinia virus recombinants: role of residual virulence of recombinants and immunogenicity of extrinsic antigens.
Kutinová L; Ludvíková V; Nemecková S; Hainz P; Simonová V; Vonka V
Vaccine; 1999 Mar; 17(9-10):1186-92. PubMed ID: 10195631
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines.
Meseda CA; Atukorale V; Kuhn J; Schmeisser F; Weir JP
PLoS One; 2016; 11(2):e0149364. PubMed ID: 26895072
[TBL] [Abstract][Full Text] [Related]
12. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen.
Smith GL; Mackett M; Moss B
Nature; 1983 Apr; 302(5908):490-5. PubMed ID: 6835382
[TBL] [Abstract][Full Text] [Related]
13. Influence of the parental virus strain on the virulence and immunogenicity of recombinant vaccinia viruses expressing HBV preS2-S protein or VZV glycoprotein I.
Kutinová L; Ludvíková V; Krystofová J; Otavová M; Simonová V; Nĕmecková S; Hainz P; Vonka V
Vaccine; 1996 Aug; 14(11):1045-52. PubMed ID: 8879101
[TBL] [Abstract][Full Text] [Related]
14. [A recombinant vaccinia virus expressing the middle preS2-S envelope protein of the hepatitis B virus. The induction of humoral and cellular immunity by the immunization of laboratory animals].
Beliaev AS; Dmitriev IP; Ignat'ev GM; Mizenko GA; Putintseva NI; Sabirov AN; Samukov VV; Semënova LN; Ammosov AD; Rukavishnikov MIu
Dokl Akad Nauk SSSR; 1990; 314(2):488-91. PubMed ID: 2265587
[No Abstract] [Full Text] [Related]
15. Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge.
Stott EJ; Ball LA; Young KK; Furze J; Wertz GW
J Virol; 1986 Nov; 60(2):607-13. PubMed ID: 3773052
[TBL] [Abstract][Full Text] [Related]
16. Induction of immune responses in cattle with a DNA vaccine encoding glycoprotein C of bovine herpesvirus-1.
Gupta PK; Saini M; Gupta LK; Rao VD; Bandyopadhyay SK; Butchaiah G; Garg GK; Garg SK
Vet Microbiol; 2001 Feb; 78(4):293-305. PubMed ID: 11182496
[TBL] [Abstract][Full Text] [Related]
17. Genetically engineered poxviruses: a novel approach to the construction of live vaccines.
Paoletti E; Weinberg RL; Davis SW; Davis M
Vaccine; 1984 Sep; 2(3):204-8. PubMed ID: 6099648
[TBL] [Abstract][Full Text] [Related]
18. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.
Rooney JF; Wohlenberg C; Cremer KJ; Moss B; Notkins AL
J Virol; 1988 May; 62(5):1530-4. PubMed ID: 2833606
[TBL] [Abstract][Full Text] [Related]
19. Induction of protective immunity with antibody to herpes simplex virus type 1 glycoprotein H (gH) and analysis of the immune response to gH expressed in recombinant vaccinia virus.
Forrester AJ; Sullivan V; Simmons A; Blacklaws BA; Smith GL; Nash AA; Minson AC
J Gen Virol; 1991 Feb; 72 ( Pt 2)():369-75. PubMed ID: 1704412
[TBL] [Abstract][Full Text] [Related]
20. Immunisation of cattle with a recombinant togavirus-vaccinia virus strain.
Franke CA; Berry ES; Smith AW; Hruby DE
Res Vet Sci; 1985 Jul; 39(1):113-5. PubMed ID: 3862196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
